MA50156A - Variants d'anticorps - Google Patents

Variants d'anticorps

Info

Publication number: MA50156A
Authority: MA; Morocco
Prior art keywords: antibody variants; variants; antibody
Prior art date: 2017-09-19

Application number

MA050156A

Other languages

English (en)

Inventor

Esther Maria Furrer

Original Assignee

Tillotts Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-19

Filing date

2018-09-11

Publication date

2020-07-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59923275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-09-11 Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag

2020-07-29 Publication of MA50156A publication Critical patent/MA50156A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

MA050156A 2017-09-19 2018-09-11 Variants d'anticorps MA50156A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP17191989.7A EP3456738B1 (fr)	2017-09-19	2017-09-19	Variantes d'anticorps

Publications (1)

Publication Number	Publication Date
MA50156A true MA50156A (fr)	2020-07-29

Family

ID=59923275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050156A MA50156A (fr)	2017-09-19	2018-09-11	Variants d'anticorps

Country Status (26)

Country	Link
US (2)	US11999781B2 (fr)
EP (3)	EP3456738B1 (fr)
JP (2)	JP7240385B2 (fr)
KR (2)	KR102761321B1 (fr)
CN (2)	CN111094343B (fr)
AR (1)	AR113303A1 (fr)
AU (2)	AU2018337495B2 (fr)
BR (1)	BR112020005482A2 (fr)
CA (1)	CA3075959A1 (fr)
CL (1)	CL2020000721A1 (fr)
CO (1)	CO2020003260A2 (fr)
CR (2)	CR20200132A (fr)
EA (1)	EA202090617A1 (fr)
ES (1)	ES2991804T3 (fr)
GE (4)	GEP20237484B (fr)
IL (2)	IL320817A (fr)
JO (1)	JOP20200063B1 (fr)
MA (1)	MA50156A (fr)
MX (1)	MX2020002989A (fr)
PH (1)	PH12020500473A1 (fr)
SA (1)	SA520411559B1 (fr)
SG (1)	SG11202002220TA (fr)
TW (1)	TWI873084B (fr)
UA (1)	UA129515C2 (fr)
WO (1)	WO2019057564A1 (fr)
ZA (1)	ZA202001830B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20250036943A (ko)	2016-08-02	2025-03-14	비스테라, 인크.	조작된 폴리펩티드 및 그의 용도
WO2020114616A1 (fr)	2018-12-07	2020-06-11	Tillotts Pharma Ag	Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci
WO2026055315A1 (fr)	2024-09-05	2026-03-12	Stirx, Inc.	Anticorps monoclonaux humanisés, procédés de fabrication et de traitement de neisseria gonorrhea

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2672640T3 (es) *	2003-11-05	2018-06-15	Roche Glycart Ag	Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US7645450B2 (en) *	2004-12-29	2010-01-12	Yuhan Corporation	Humanized antibody specific for tumor necrosis factor-alpha
CN101120021A (zh)	2004-12-31	2008-02-06	基因技术公司	结合br3的多肽及其用途
PL2808343T3 (pl) *	2007-12-26	2019-11-29	Xencor Inc	Warianty Fc ze zmienionym wiązaniem do FcRn
RU2653753C1 (ru) *	2008-06-25	2018-05-14	ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи	СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
CA2943445A1 (fr)	2014-03-26	2015-10-01	Cell Medica Switzerland Ag	Elements de liaison diriges contre tnf alpha
CN106255704A (zh) *	2014-04-16	2016-12-21	Ucb生物制药私人有限公司	多聚体Fc蛋白
CR20180365A (es) *	2015-12-16	2018-09-28	Amgen Inc	PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CR20180445A (es) *	2016-03-14	2019-02-08	Univ Oslo	Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
EP3219726B1 (fr) *	2016-03-17	2020-12-02	Tillotts Pharma AG	Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci

2017
- 2017-09-19 ES ES17191989T patent/ES2991804T3/es active Active
- 2017-09-19 EP EP17191989.7A patent/EP3456738B1/fr active Active
- 2017-09-19 EP EP24188725.6A patent/EP4424707A3/fr not_active Withdrawn
2018
- 2018-09-11 CR CR20200132A patent/CR20200132A/es unknown
- 2018-09-11 CR CR20210205A patent/CR20210205A/es unknown
- 2018-09-11 KR KR1020207009263A patent/KR102761321B1/ko active Active
- 2018-09-11 GE GEAP201815316A patent/GEP20237484B/en unknown
- 2018-09-11 WO PCT/EP2018/074522 patent/WO2019057564A1/fr not_active Ceased
- 2018-09-11 GE GEAP202215316A patent/GEAP202215316A/en unknown
- 2018-09-11 IL IL320817A patent/IL320817A/en unknown
- 2018-09-11 EA EA202090617A patent/EA202090617A1/ru unknown
- 2018-09-11 SG SG11202002220TA patent/SG11202002220TA/en unknown
- 2018-09-11 MA MA050156A patent/MA50156A/fr unknown
- 2018-09-11 AU AU2018337495A patent/AU2018337495B2/en active Active
- 2018-09-11 EP EP18762890.4A patent/EP3684807A1/fr active Pending
- 2018-09-11 CN CN201880060497.2A patent/CN111094343B/zh active Active
- 2018-09-11 GE GEAP201815617A patent/GEP20247700B/en unknown
- 2018-09-11 IL IL273351A patent/IL273351B2/en unknown
- 2018-09-11 KR KR1020257002596A patent/KR20250022222A/ko active Pending
- 2018-09-11 CA CA3075959A patent/CA3075959A1/fr active Pending
- 2018-09-11 MX MX2020002989A patent/MX2020002989A/es unknown
- 2018-09-11 UA UAA202002075A patent/UA129515C2/uk unknown
- 2018-09-11 BR BR112020005482-8A patent/BR112020005482A2/pt unknown
- 2018-09-11 GE GEAP202415617A patent/GEAP202415617A/en unknown
- 2018-09-11 CN CN202411095846.8A patent/CN119409817A/zh active Pending
- 2018-09-11 US US16/648,537 patent/US11999781B2/en active Active
- 2018-09-11 JP JP2020516456A patent/JP7240385B2/ja active Active
- 2018-09-17 TW TW107132681A patent/TWI873084B/zh active
- 2018-09-19 AR ARP180102664A patent/AR113303A1/es unknown
2020
- 2020-03-09 PH PH12020500473A patent/PH12020500473A1/en unknown
- 2020-03-17 JO JOJO/P/2020/0063A patent/JOP20200063B1/ar active
- 2020-03-18 SA SA520411559A patent/SA520411559B1/ar unknown
- 2020-03-19 CO CONC2020/0003260A patent/CO2020003260A2/es unknown
- 2020-03-19 CL CL2020000721A patent/CL2020000721A1/es unknown
- 2020-03-23 ZA ZA2020/01830A patent/ZA202001830B/en unknown
2022
- 2022-12-27 JP JP2022210008A patent/JP7402304B2/ja active Active
2024
- 2024-06-03 US US18/732,335 patent/US20240343793A1/en active Pending
- 2024-12-24 AU AU2024287208A patent/AU2024287208A1/en active Pending

Also Published As

Publication number	Publication date
JP7240385B2 (ja)	2023-03-15
EP3456738A1 (fr)	2019-03-20
KR102761321B1 (ko)	2025-02-04
CA3075959A1 (fr)	2019-03-28
CR20210205A (es)	2021-07-27
JOP20200063A1 (ar)	2020-03-17
US20240343793A1 (en)	2024-10-17
ZA202001830B (en)	2024-10-30
UA129515C2 (uk)	2025-05-21
EP3456738C0 (fr)	2024-07-17
IL320817A (en)	2025-07-01
CN111094343A (zh)	2020-05-01
EP4424707A3 (fr)	2024-11-13
CN119409817A (zh)	2025-02-11
BR112020005482A2 (pt)	2020-09-29
AU2024287208A1 (en)	2025-02-13
TWI873084B (zh)	2025-02-21
IL273351B1 (en)	2025-06-01
CO2020003260A2 (es)	2020-04-13
EP3456738B1 (fr)	2024-07-17
AU2018337495A1 (en)	2020-04-09
EP4424707A2 (fr)	2024-09-04
GEAP202215316A (en)	2022-10-25
KR20250022222A (ko)	2025-02-14
MX2020002989A (es)	2020-07-22
JP7402304B2 (ja)	2023-12-20
IL273351B2 (en)	2025-10-01
IL273351A (en)	2020-05-31
GEP20247700B (en)	2024-11-25
SG11202002220TA (en)	2020-04-29
GEAP202415617A (en)	2024-06-25
CL2020000721A1 (es)	2020-08-07
JOP20200063B1 (ar)	2024-12-22
EA202090617A1 (ru)	2020-07-27
EP3684807A1 (fr)	2020-07-29
GEP20237484B (en)	2023-03-27
AU2018337495B2 (en)	2024-10-17
US11999781B2 (en)	2024-06-04
SA520411559B1 (ar)	2024-03-19
JP2020534307A (ja)	2020-11-26
TW201915021A (zh)	2019-04-16
CR20200132A (es)	2020-07-24
KR20200053514A (ko)	2020-05-18
AR113303A1 (es)	2020-04-08
WO2019057564A1 (fr)	2019-03-28
CN111094343B (zh)	2024-09-20
ES2991804T3 (es)	2024-12-04
PH12020500473A1 (en)	2021-01-25
JP2023036885A (ja)	2023-03-14
US20200216527A1 (en)	2020-07-09

Publication	Publication Date	Title
EP3903817A4 (fr)	2022-08-17	Nouvel anticorps anti-ccr8
MA52884A (fr)	2021-04-21	Anticorps anti-il-11
MA53434A (fr)	2021-12-01	Anticorps anti-tigit
EP3589313A4 (fr)	2021-05-19	Anticorps anti-tigit
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
MA49043A (fr)	2020-02-12	Formulation stable d'anticorps
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
EP3359573A4 (fr)	2019-05-29	Marquage d'anticorps
MA52366A (fr)	2021-03-03	Anticorps anti-tl1a optimisés
EP3883970A4 (fr)	2022-03-30	Anticorps anti-b7-h3
EP3484518A4 (fr)	2020-04-22	Conjugués d'adjuvant d'anticorps
MA44236A (fr)	2018-12-26	Anticorps anti-tgfbêta 2
EP3498840A4 (fr)	2020-05-06	Anticorps anti-lag-3
MA49749A (fr)	2021-03-24	Anticorps anti-cd137
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
EP3807318A4 (fr)	2022-03-02	Constructions d'anticorps multi-spécifiques
EP3617231A4 (fr)	2021-04-07	Anticorps anti-gpc-1
EP3492591A4 (fr)	2020-04-01	Anticorps anti-b7-h4
EP3692072A4 (fr)	2021-12-22	Anticorps anti-hla-dq2.5
MA51134A (fr)	2021-03-24	Anticorps anti-alpha-synucléine
EP3526247A4 (fr)	2021-04-14	Anticorps anti-il1-rap
EP3399992A4 (fr)	2019-07-31	Anticorps autoréticulants
MA52152A (fr)	2021-01-20	Anticorps
EP3484919A4 (fr)	2020-03-04	Anticorps anti-bêta-amyloïde
MA54052A (fr)	2022-02-09	Formulation d'anticorps